We are live on ! Find out more
IMRX icon

Immuneering
IMRX

34 hedge funds and large institutions have $115M invested in Immuneering in 2023 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 13 increasing their positions, 12 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

102% more capital invested

Capital invested by funds: $56.9M → $115M (+$58M)

8% more repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 12

0.33% more ownership

Funds ownership: 44.39% → 44.72% (+0.33%)

0% more funds holding

Funds holding: 34 → 34 (0)

0% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 6

Holders
34
Holders Change
–
Holders Change %
0%
% of All Funds
0.54%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
13
Reduced
12
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$1.42M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$738K
3
CAM
Cormorant Asset Management
Massachusetts
+$568K
4
Bank of Montreal
Bank of Montreal
Ontario, Canada
+$545K
5
ECM
ExodusPoint Capital Management
New York
+$490K

Top Sellers

Rank Fund Capital Flow
1
T. Rowe Price Investment Management
T. Rowe Price Investment Management
Maryland
-$2.22M
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$915K
3
Citadel Advisors
Citadel Advisors
Florida
-$209K
4
AFM
Anson Funds Management
Texas
-$158K
5
GCP
GSA Capital Partners
United Kingdom
-$113K
Name Holding Trade Value Shares
Change 		Change in
Stake
UBS Group
26
UBS Group
Switzerland
$26.3K +$15.4K +2,713 New
Bank of America
27
Bank of America
North Carolina
$23.2K +$10.6K +1,861 +350%
JP Morgan Chase
28
JP Morgan Chase
New York
$10K +$397 +70 +7%
CUAMC
29
China Universal Asset Management Company
China
$3.48K +$511 +90 +34%
CSPIA
30
Cary Street Partners Investment Advisory
Virginia
$2.92K +$1.71K +301 New
Citigroup
31
Citigroup
New York
$2.91K -$585 -103 -26%
Wells Fargo
32
Wells Fargo
California
$1.22K +$11 +2 +2%
Daiwa Securities Group
33
Daiwa Securities Group
Japan
$1K – – –
Zurich Cantonal Bank
34
Zurich Cantonal Bank
Switzerland
$49 -$23.5K -4,143 -100%
T. Rowe Price Investment Management
35
T. Rowe Price Investment Management
Maryland
– -$2.22M -458,233 Closed
AFM
36
Anson Funds Management
Texas
– -$158K -32,603 Closed
GCP
37
GSA Capital Partners
United Kingdom
– -$113K -23,371 Closed
Qube Research & Technologies (QRT)
38
Qube Research & Technologies (QRT)
United Kingdom
– -$94.1K -19,394 Closed
Royal Bank of Canada
39
Royal Bank of Canada
Ontario, Canada
– -$432 -76 -94%
CS
40
Credit Suisse
Switzerland
– -$281 -58 Closed
1
2

IMRX Hedge Fund Activity: Q1 2023 in Review

34 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Immuneering (IMRX) for Q1 2023, worth a combined $115M — up 102% from $56.9M a quarter earlier.

Fund positioning in IMRX was balanced in Q1 2023: 6 funds opened new positions, 6 closed out, 13 added to existing stakes and 12 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $1.42M. The largest seller was T. Rowe Price Investment Management, exiting entirely with an estimated $2.22M sold.

  • 34 institutional investors held Immuneering (IMRX) as of Q1 2023, unchanged from Q4 2022.
  • Funds reported $115M of Immuneering stock for Q1 2023, up 102% quarter-over-quarter.
  • 6 funds opened new Immuneering positions in Q1 2023 and 6 closed out, a net change of 0 holders.
  • The largest Immuneering buyer in Q1 2023 was Fidelity Investments, an estimated $1.42M added.
  • The largest Immuneering seller in Q1 2023 was T. Rowe Price Investment Management, an estimated $2.22M sold.

Based on aggregated 13F filings for Q1 2023.